Clinical Research Directory
Browse clinical research sites, groups, and studies.
Effect of GH on the Blastocyst Euploid Rate in AMA Patients
Sponsor: ShangHai Ji Ai Genetics & IVF Institute
Summary
This randomized trial aims to compare the euploid rate of blastocysts in AMA patients undergoing PGT-A (preimplantation genetic testing for aneuploidy) with or without growth hormone supplement. Infertile patients ≥38 years old will be recruited for study after informed consent if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Treatment group: Women will receive growth hormone (GH) supplement before and during antagonist protocol for ovarian stimulation. Control group: Women will receive antagonist protocol for ovarian stimulation. The primary outcome is the euploidy rate of blastocysts.
Official title: A Randomized Control Trial to Investigate the Effect of Growth Hormone on the Euploid Rate of Blastocyst in Patients With Advanced Maternal Age
Key Details
Gender
FEMALE
Age Range
38 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2022-08-01
Completion Date
2026-12-31
Last Updated
2025-02-12
Healthy Volunteers
No
Interventions
Growth Hormone
Growth hormone is supplemented before and during the ovarian stimulation till the day of oocyte retrieval
GnRH antagonist
GnRH antagonist (Cetrorelix 0.25mg) once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger
Locations (1)
Shanghai JIAI Genetics and IVF Institute
Shanghai, Shanghai Municipality, China